Inhalational anthrax

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:247257A22.1
Who is this for?
Show terms as
2FDA treatments25Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Inhalational anthrax, also called woolsorters' disease or pulmonary anthrax, is a serious and life-threatening infection caused by breathing in spores of the bacterium Bacillus anthracis. This is not a genetic disease — it is an infectious disease that occurs when a person inhales enough spores to trigger an infection in the lungs and surrounding tissues. Once inside the body, the spores travel to lymph nodes in the chest, where they activate and begin producing powerful toxins that damage the body's organs and immune system. The disease typically starts with mild, flu-like symptoms such as fever, fatigue, and mild chest discomfort. This early stage can be deceptive because it may seem like a common illness. However, within one to three days, the condition can rapidly worsen into a severe, life-threatening emergency with difficulty breathing, shock, and widespread infection in the blood (septicemia). The chest cavity may fill with fluid, making breathing extremely difficult. Inhalational anthrax is considered the most dangerous form of anthrax infection. Treatment relies on powerful antibiotics such as ciprofloxacin, doxycycline, and amoxicillin, often combined with antitoxin medications. Early treatment dramatically improves survival chances. Without prompt treatment, the disease is almost always fatal. Because of its potential use as a bioterrorism agent, inhalational anthrax is closely monitored by public health authorities worldwide.

Also known as:

Key symptoms:

Fever and chillsExtreme tiredness and weaknessMild chest pain or discomfortShortness of breath that gets worse quicklySweating, including night sweatsNausea and vomitingHeadacheConfusion or altered mental stateRapid heart rateLow blood pressure (shock)Swelling in the neck or chest areaBluish skin color due to lack of oxygenFluid buildup around the lungs

Clinical phenotype terms (12)— hover any for plain English
Abnormal sweat gland morphologyHP:0000971Focal autonomic seizure with epigastric sensation/nausea/vomiting/other gastrointestinal phenomenaHP:0011159Incomprehensible speechHP:0002546Internal hemorrhageHP:0011029
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

3 events
Nov 2035Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

Emergent BioSolutions

TrialNOT YET RECRUITING
May 2027A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Emergent BioSolutions

TrialNOT YET RECRUITING
Dec 2012

ABthraxTM: FDA approved

Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Anthim

obiltoxaximab· Elusys Therapeutics, Inc.■ Boxed Warning

indicated in adult and pediatric patients for the treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs

ABthraxTM

raxibacumab· Human Genome Sciences, Inc.■ Boxed WarningOrphan Drug

Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,

No actively recruiting trials found for Inhalational anthrax at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Inhalational anthrax community →

Specialists

25 foundView all specialists →
AM
Alex King, MD
Specialist
PI on 2 active trials1 Inhalational anthrax publication
DM
David Mathews, MD
Specialist
PI on 2 active trials
LM
Lori Sieboldt, MD
EVANSVILLE, IN
Specialist
PI on 1 active trial1 Inhalational anthrax publication
HM
H. Frank Farmer, PhD, MD
Specialist
PI on 1 active trial
AP
Alan S Marion, MD, PhD
Specialist
PI on 1 active trial
JM
Jolene Berg, MD
EDINA, MN
Specialist
PI on 1 active trial
DM
Debra Mandarino, MD
MADISON, WI
Specialist
PI on 2 active trials
TJ
Tammy D Jenkins
Specialist
1 Inhalational anthrax publication
SR
Sherry L Rippeon
Specialist
1 Inhalational anthrax publication
JM
James E Miller
Specialist
1 Inhalational anthrax publication
DT
Derek Toth
MOUNT PLEASANT, SC
Specialist
2 Inhalational anthrax publications
JB
Jeremy A Boydston
Specialist
1 Inhalational anthrax publication
SK
Srinivas Kammanadiminti
Specialist
2 Inhalational anthrax publications
AF
Allison M Ferris
LIBERTY, MO
Specialist
1 Inhalational anthrax publication
DD
David G Dawson
Specialist
1 Inhalational anthrax publication
MK
Melissa L Krause
Specialist
1 Inhalational anthrax publication
CB
Charles L Balzli
Specialist
1 Inhalational anthrax publication
VW
Victoria Wahl
Specialist
1 Inhalational anthrax publication
JY
John J Yeager
BEL AIR, MD
Specialist
1 Inhalational anthrax publication
JB
Jordan K Bohannon
Specialist
1 Inhalational anthrax publication
SK
Shantha Kodihalli
Specialist
2 Inhalational anthrax publications
AE
Andrea B Eyler
Specialist
1 Inhalational anthrax publication
BE
Brandon Essink
CREIGHTON, NE
Specialist
PI on 1 active trial
OP
Oscar Della Pasqua
Specialist
2 Inhalational anthrax publications
SO
Sean P Oosterholt
Specialist
2 Inhalational anthrax publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Inhalational anthrax.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Inhalational anthraxForum →

No community posts yet. Be the first to share your experience with Inhalational anthrax.

Start the conversation →

Latest news about Inhalational anthrax

No recent news articles for Inhalational anthrax.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How certain are you that this is inhalational anthrax, and what tests confirmed the diagnosis?,Which antibiotics will I be given, and how long will I need to take them?,Will I receive antitoxin treatment, and what are the benefits and risks?,What are the signs that my condition is improving or getting worse?,Is there any risk to my family members or people I have been in contact with?,What long-term effects on my lungs or other organs should I watch for after recovery?,Are there any public health steps I or my family need to take, such as preventive antibiotics or vaccination?

Common questions about Inhalational anthrax

What is Inhalational anthrax?

Inhalational anthrax, also called woolsorters' disease or pulmonary anthrax, is a serious and life-threatening infection caused by breathing in spores of the bacterium Bacillus anthracis. This is not a genetic disease — it is an infectious disease that occurs when a person inhales enough spores to trigger an infection in the lungs and surrounding tissues. Once inside the body, the spores travel to lymph nodes in the chest, where they activate and begin producing powerful toxins that damage the body's organs and immune system. The disease typically starts with mild, flu-like symptoms such as f

How is Inhalational anthrax inherited?

Inhalational anthrax follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat Inhalational anthrax?

25 specialists and care centers treating Inhalational anthrax are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Inhalational anthrax?

2 patient support programs are currently tracked on UniteRare for Inhalational anthrax. See the treatments and support programs sections for copay assistance, eligibility, and contact details.